Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

Blood

Volumn 113, Issue 25, 2009, Pages 6315-6321

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Jones, Dan ^a   Shan, Jianqin ^a   Borthakur, Gautam ^a   Thomas, Deborah ^a   Kornblau, Steven ^a   O'Brien, Susan ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMATINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RNA; TUMOR MARKER;

ABL1 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; BCR ABL GENE; BLAST CELL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; GENE; GENETIC TRANSCRIPTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; BLOOD; BONE MARROW CELL; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; REMISSION; RISK; STATISTICS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RISK; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650587143     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-166694     Document Type: Article

References (20)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
3. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003; 102:83-86. (Pubitemid 36759639)
4. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103:2873-2878. (Pubitemid 38451654)
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
6. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432. (Pubitemid 40627896)
7. Iacobucci I, Rosti G, Amabile M, et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol. 2006;24:454-459. (Pubitemid 46630464)
8. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
9. Branford S, Rudzki Z, Parkinson I, et al. Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926-2932. (Pubitemid 39434981)
10. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy: the Leukemia Service. Ann Intern Med. 1995;122:254-261.
11. Hochhaus A, Weisser A, La Rosee P, et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia. 2000; 14:998-1005. (Pubitemid 30389503)
12. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 2000;95: 62-66.
13. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041. (Pubitemid 36173155)
14. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:569-584. (Pubitemid 38969132)
15. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330-3338.
16. Guilhot F, Larson RA, O'Brien SG, et al. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood. 2007;110:27.
17. Cortes J, O'Brien S, Borthakur G, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood. 2008;112: 182.
18. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CMLCP). Blood. 2008;112:446.
19. Rosti G, Castagnetti F, Poerio A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CMLWorking Party. Blood. 2008; 112:181.
20. Cortes J, Baccarani M, Guilhot F, et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CMLCP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood. 2008;112:335.